AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05209841
Drug: Low dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
Trial: NCT05209841
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheters will be sealed with 3mL of 0.9% sodium chloride
Trial: NCT04436458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
Trial: NCT04860960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5N saline provided every 2 weeks intravenously
Trial: NCT05823467
Drug: TMP-SMX DS
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Antibiotic - used to treat post operative wound infections.
Trial: NCT04984278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oromucosal spray
Trial: NCT04518306
Drug: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04518306
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04518306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03390530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05326763
Drug: Dextrose 50%
RxNorm normalized name: DEXTROSE 50% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
Trial: NCT05448547
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
Trial: NCT06431438
Drug: TQA3810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Trial: NCT05388058
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT05900089
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
Trial: NCT05528913
Drug: Fasenra Prefilled Syringe
RxNorm normalized name: Fasenra Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasenra 60mg s.c. administration at weeks 0,4 and 8
Trial: NCT04768842
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06193148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo orally for single dose
Trial: NCT06242418
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
Trial: NCT06242418
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
Trial: NCT05180175
Drug: Top down treatment if patient at high risk
RxNorm normalized name: Kool-Down Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
Trial: NCT04891497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 240mg orally twice daily for 3 consecutive days
Trial: NCT05228834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Trial: NCT05548491
Drug: AZR-MD-001 ointment/semi-solid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ointment/semi-solid drug
Trial: NCT05346848
Drug: Association of ADT and EBRT
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Trial: NCT05055934
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05525234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Trial: NCT05090904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06730802
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
Trial: NCT06730802
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group will receive standard statin therapy.
Trial: NCT04405180
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
Trial: NCT05935306
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
Trial: NCT04734275
Drug: AZD5718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
Trial: NCT05320133
Drug: JWC containing quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
Trial: NCT05320133
Drug: Bismuth-containing quadruple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
Trial: NCT05672212
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil
Trial: NCT05646758
Drug: TQB2934 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Trial: NCT05852197
Drug: anticoagulant or antiplatelet drugs
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of anticoagulant or antiplatelet drugs
Trial: NCT05467670
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
Trial: NCT05114499
Drug: GV-971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV-971 450mg bid
Trial: NCT05988710
Drug: Buccal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for buccal administration
Trial: NCT05988710
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral administration
Trial: NCT06449508
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
Trial: NCT05551689
Drug: Psychostimulant
RxNorm normalized name: Psychostimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
Trial: NCT06286475
Drug: VRG50635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06286475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06188104
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
Trial: NCT06624384
Drug: Group 1 drug
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
Trial: NCT06624384
Drug: Group 2: Drug and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Trial: NCT06624384
Drug: Group 3: Drug and palcebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Trial: NCT05861102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo orally twice daily for 16 weeks
Trial: NCT04618211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral use
Trial: NCT06731348
Drug: restricted opioid prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
Trial: NCT06731348
Drug: standard opioid prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
Trial: NCT06625814
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single oral dose
Trial: NCT06730620
Drug: Test preparation：Methylcholine chloroacetate for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonists
Trial: NCT05550441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo group received placebo for 1 year.
Trial: NCT05040022
Drug: Pneumoperitoneum pressure 10 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
Trial: NCT05040022
Drug: Pneumoperitoneum pressure 14 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
Trial: NCT00001047
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05236972
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
Trial: NCT06622291
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
Trial: NCT05156645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted by 0.9% normal saline
Trial: NCT05177835
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive ABX464 given at 25 mg QD.
Trial: NCT05771402
Drug: NAs
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once/day, 1 capsule/time, oral
Trial: NCT06303128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given prior to amoxicillin 250mg in one-dose group
Trial: NCT05595408
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin/carboplatin-gemcitabine 4-6 cycles
Trial: NCT05320068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A blinded capsule that contains no vancomycin every 6 hours during 10 days.
Trial: NCT04865211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of saline as placebo for local anesthesia
Trial: NCT05693545
Drug: intramuscular benzathine penicillin G (BPG) prophylaxis
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis
Trial: NCT06304740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection of Placebo
Trial: NCT05020704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT04994561
Drug: Study Drugs and Nutritional Supplements
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months.
Trial: NCT05071716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Twice Daily
Trial: NCT06189404
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg oral dose
Trial: NCT00076960
Drug: Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 4.5 mg/kg
Trial: NCT04616014
Drug: ORMD-0801 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg, QD, two capsules, 8 mg each.
Trial: NCT06619665
Drug: MK-6552
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-6552 gelatin coated capsules taken orally two times 8 hours apart
Trial: NCT06619665
Drug: MK-6552 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Trial: NCT05745207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2086 matched placebo tablets.
Trial: NCT05869682
Drug: Combination Drug Therapy
RxNorm normalized name: BILE THERAPY DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive SOC ADT combination therapy
Trial: NCT06455124
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Trial: NCT05497336
Drug: IBI351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI351 is administered orally
Trial: NCT00365001
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg po/week
Trial: NCT00365001
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg po on days 1, 15 and 43
Trial: NCT04659629
Drug: NL-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NL-201 is a de novo protein therapeutic.
Trial: NCT06360120
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Trial: NCT05804734
Drug: Vitamin K Antagonist - Drug
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment.
Trial: NCT06053983
Drug: rosuvastatin 20 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
Trial: NCT04485130
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Trial: NCT04485130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
Trial: NCT05362695
Drug: IW-3300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
Trial: NCT05362695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
Trial: NCT06435767
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
Trial: NCT01134497
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
Trial: NCT06098144
Drug: Nicoderm C-Q Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition.
Trial: NCT05094947
Drug: alpha-blockers
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin, alfuzosin, doxazosin, silodosin